- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12. | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology | 3 | GlobeNewswire (USA) | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11. | Earnings Call: Journey Medical meldet Umsatzwachstum für Q3 2025 und stellt positives EBITDA in Aussicht | 6 | Investing.com Deutsch | ||
| 12.11. | Journey Medical GAAP EPS of -$0.09, revenue of $17.6M | 2 | Seeking Alpha | ||
| 12.11. | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 150 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| 12.11. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.11. | Insights into Journey Medical's Upcoming Earnings | 13 | Benzinga.com | ||
| 05.11. | Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 | 2 | GlobeNewswire (USA) | ||
| 24.10. | Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea | 2 | RTTNews | ||
| 24.10. | Journey Medical's Emrosi shows superior efficacy for rosacea | 1 | Investing.com | ||
| 26.09. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09. | Summers Value Partners' Update on Journey Medical (DERM) | 6 | Insider Monkey | ||
| 28.08. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | H.C. Wainwright stuft Journey Medical mit "Kaufen" ein - Rosacea-Medikament Emrosi als entscheidender Faktor | 9 | Investing.com Deutsch | ||
| 25.08. | H.C. Wainwright initiates Journey Medical stock with Buy rating on Emrosi potential | 2 | Investing.com | ||
| 20.08. | Journey Medical setzt auf Rosacea-Mittel Imrozi für Profitabilitätswende | 5 | Investing.com Deutsch | ||
| 13.08. | Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples | 5 | Seeking Alpha | ||
| 12.08. | Journey Medical Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 12.08. | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 568 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
| 12.08. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Examining the Future: Journey Medical's Earnings Outlook | 2 | Benzinga.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,420 | +0,30 % | Opening Bell: Pfizer, Nike, Tilray, D-Wave, Roku, PayPal, Apple, AMC Robotics | Die US-Börsen haben ihre Verluste zum Wochenauftakt fortgesetzt. Der Dow Jones schloss nahezu unverändert 0,09 Prozent tiefer bei 48.416,56 Punkten, während der Nasdaq Composite deutlicher nachgab und... ► Artikel lesen | |
| GILEAD SCIENCES | 103,94 | +0,50 % | Dividendenbekanntmachungen (15.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2969 EUR AMERICAN HOMES 4 RENT US02665T3068 0,3 USD 0,2555 EUR ARES CAPITAL... ► Artikel lesen | |
| ELI LILLY | 903,30 | +1,79 % | Märkte am Morgen: Silber, Oracle, Broadcom, Eli Lilly, Munich Re, SAP, ASML | Der deutsche Aktienmarkt muss in dieser Woche einige Impulse aus den USA verarbeiten. Letzten Endes setzten sich die positiven Impulse der Leitzinssenkung der US-Notenbank durch - der DAX legte deutlich... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 382,15 | -0,25 % | Vertex Presents New CASGEVY Data Highlighting Benefits In Children Ages 5-11 | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced new data from pivotal studies of CASGEVY (exagamglogene autotemcel), demonstrating the transformative... ► Artikel lesen | |
| EYEPOINT | 14,645 | +3,17 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| ASTRIA THERAPEUTICS | 10,700 | -0,93 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 167,00 | +0,60 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 141,20 | +0,50 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Upcoming Investor Events | DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events:
Zanidatamab HERIZON-GEA-01... ► Artikel lesen | |
| OPKO HEALTH | 1,068 | +0,21 % | OPKO Health, Inc.: OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results | MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights... ► Artikel lesen | |
| UNITED THERAPEUTICS | 433,50 | -0,44 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| ROYALTY PHARMA | 32,950 | +0,98 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,330 | -0,59 % | Molly Harper Takes Money Off The Table, Sells $621K In Catalyst Pharmaceuticals Stock | ||
| BRIDGEBIO PHARMA | 63,06 | 0,00 % | Bernstein initiates BridgeBio Pharma stock coverage with Outperform rating | ||
| TG THERAPEUTICS | 26,335 | -0,74 % | TG Therapeutics, Inc.: TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI | NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated... ► Artikel lesen | |
| AVADEL PHARMACEUTICALS | 17,600 | 0,00 % | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ Trial in Idiopathic Hypersomnia | - Data expected in Q2 2026 - DUBLIN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives,... ► Artikel lesen |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,140 (+1,80 %) liegt der Kurs bei 7,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.